Related Experiment Videos
Tamoxifen and cataracts: a null association
Brian D Bradbury1, Timothy L Lash, James A Kaye
1Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA. bdb2@bu.edu
Breast Cancer Research and Treatment
|September 21, 2004
Summary
Tamoxifen treatment for breast cancer patients does not increase cataract risk. This study found no link between tamoxifen use and developing cataracts in women.
Area of Science:
- Oncology
- Ophthalmology
- Pharmacoepidemiology
Background:
- Previous research suggested a potential link between tamoxifen and increased cataract risk in breast cancer patients.
- This study aimed to rigorously assess the association between tamoxifen treatment and cataract development.
Purpose of the Study:
- To determine if breast cancer patients treated with tamoxifen have a higher risk of developing cataracts compared to women not prescribed tamoxifen.
- To investigate the relationship between tamoxifen use, including current, past, and cumulative exposure, and cataract incidence.
Main Methods:
- A nested, matched case-control study design was employed using the General Practice Research Database.
- Women aged 30-79 diagnosed with breast cancer and treated with tamoxifen, or other cancers, between 1991-1999 were identified.
- Four controls were matched to each cataract case based on age and dates; adjusted odds ratios were calculated.
Main Results:
- Current tamoxifen users showed no increased risk of cataract (Adjusted Odds Ratio = 1.0, 95% Confidence Interval: 0.7, 1.4).
- No association was found between increasing cumulative tamoxifen dose and cataract risk.
Conclusions:
- No increased risk of cataract was detected in breast cancer patients treated with tamoxifen.
- The findings suggest tamoxifen therapy is not associated with a higher incidence of cataracts in this patient population.